3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Non-Hodgkin
7
Lymphoma
7
Glioblastoma
7
Lymphoma, Large B-Cell, Diffuse
5
Hodgkin Disease
5
Multiple Myeloma
4
Glioma
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Neoplasms, Plasma Cell
3
Neoplasms
3
Lymphoma, Mantle-Cell
3
Lymphoma, Follicular
3
Lymphoma, B-Cell
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia
3
Gliosarcoma
3
Burkitt Lymphoma
3
Brain Neoplasms
3
Astrocytoma
3
Myelodysplastic Syndromes
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, B-Cell, Marginal Zone
2
Leukemia, Myeloid, Acute
2
Central Nervous System Neoplasms
2
Anemia, Refractory, with Excess of Blasts
2
Recurrence
1
Primary Myelofibrosis
1
Pediatric Brain Tumor
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Oligodendroglioma
1
Interventions
Rituximab
4
Etoposide
3
Cyclophosphamide
3
cobomarsen
2
Vincristine
2
Prednisone
2
Ifosfamide
2
Doxorubicin
2
Carboplatin
2
Brentuximab Vedotin
2
ponatinib
1
pomalidomide
1
ibritumomab tiuxetan
1
fludarabine
1
dacetuzumab
1
Vorinostat
1
Melphalan
1
Imatinib Mesylate
1
Everolimus
1
DTRMWXHS-12
1
Cytarabine
1
Carmustine
1
Bendamustine Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphatic Diseases
×
Carmustine
×
Clear all
NCT02366663
2018-03-12
SPINOZA
City of Hope Medical Center
Phase 3
Terminated
3 enrolled
8 charts